Glutamic acid decarboxylase (GAD) antibodies in tardive dyskinesia (TD) as compared to patients with schizophrenia without TD and normal controls.
Yarlagadda
Atmaram
A
Helvink
Badalin
B
Chou
Caroline
C
Gladieux
Kenneth
K
Keller
Adrienne
A
Clayton
Anita
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000032:analysis*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019208:Brain-Derived Neurotrophic Factor / Q000276:immunology; D035061:Control Groups; D004409:Dyskinesia, Drug-Induced / Q000201:enzymology / Q000276:immunology*; D005968:Glutamate Decarboxylase / Q000276:immunology*; D006801:Humans; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology* / Q000276:immunology
D000906:Antibodies; D014150:Antipsychotic Agents; D019208:Brain-Derived Neurotrophic Factor; D005968:Glutamate Decarboxylase; C402565:glutamate decarboxylase 1; C401141:glutamate decarboxylase 2